Streetbeat News

Analyst Ratings

CTVA

Analysts have recently adjusted their ratings and price targets for Corteva (NYSE:CTVA), showing a negative shift in sentiment. The average 12-month price target is now $59.92, down 13.37% from previous estimates. Multiple analysts from firms such as UBS, Berenberg, and Morgan Stanley have lowered their price targets, reflecting changes in market conditions and company performance. Corteva's financial indicators show a decline in revenue growth, below-average net margin and ROE, and a conservative debt management approach. The company, a leader in seed and crop chemicals, was spun off from DowDuPont in 2019.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

MUR

Analysts have updated their ratings and price targets for Murphy Oil (NYSE:MUR), with 4 analysts offering diverse views. The average 12-month price target is now $52.00, up from $51.67. Tim Rezvan from Keybanc and Josh Silverstein from UBS lowered their price targets, while Neal Dingmann from Truist Securities maintained his, and Mark Lear from Piper Sandler raised his. Murphy Oil's financials show a revenue decline of -18.23% for the last quarter, a high net margin of 26.77%, but a lower than average ROE of 4.83% and a strong ROA of 2.53%. The company's debt-to-equity ratio is healthy at 0.45.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

SM

Analysts have updated their ratings and price targets for SM Energy (NYSE:SM), with a mix of bullish and neutral stances. Over the past three months, ratings have varied, with the current consensus being 1 bullish, 2 somewhat bullish, and 1 indifferent. The average 12-month price target is now $45.00, down from $47.75, with a high estimate of $51.00 and a low of $40.00. Key analysts from Keybanc, Raymond James, Mizuho, and Susquehanna have adjusted their price targets, with three lowering and one raising their target. SM Energy's financials show a -22.7% revenue decline over 3 months, but strong profitability with a net margin of 34.76% and above-average ROE and ROA. The company has a lower-than-average debt-to-equity ratio of 0.46.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

ABT

UBER

VRTX

On CNBC's Halftime Report, the final trades segment featured recommendations for Uber Technologies, Vertex Pharmaceuticals, and Abbott Laboratories. These companies were highlighted as potential investment opportunities, though specific details of the discussion were not provided in the article.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 6:00 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has received mixed analyst ratings over the past three months, with 12 analysts offering a range of bullish to bearish perspectives. The average 12-month price target is $58.5, with a high of $77.00 and a low of $37.00. However, there has been a 17.89% decrease in the average price target, indicating a negative shift in sentiment. Analysts from firms like JMP Securities, Raymond James, HC Wainwright & Co., Cantor Fitzgerald, JP Morgan, Morgan Stanley, and Evercore ISI Group have provided various ratings and price target adjustments. Mirum Pharmaceuticals is a biopharmaceutical company with a focus on rare and orphan diseases, and its product Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The company has shown a revenue growth rate of 154.13% as of September 30, 2023, but faces challenges with a net margin of -49.42% and a debt-to-equity ratio of 1.14.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

LPX

Louisiana-Pacific (NYSE:LPX) has been the subject of varying opinions from 6 analysts over the past three months, with recent ratings ranging from bullish to indifferent. The average 12-month price target for LPX has risen to $74.67, up 4.29% from the previous target of $71.60. Analysts from firms including TD Cowen, Truist Securities, RBC Capital, and Goldman Sachs have updated their price targets and ratings, reflecting their latest views on the company's performance. Louisiana-Pacific, a producer of oriented strand board and engineered wood siding, has a market cap above industry average, a negative revenue trend of -14.55% over 3 months, a high net margin of 16.21%, an ROE of 8.09%, an ROA of 5.04%, and a low debt-to-equity ratio of 0.25.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

PARA

Paramount shares have declined following a downgrade by Redburn Atlantic from Neutral to Sell, with a new price target set at $11.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 5:23 pm

TDUP

Four analysts have recently updated their ratings and price targets for ThredUp (NASDAQ:TDUP), with mixed views. The average 12-month price target is now $3.75, down from $4.00, indicating a 6.25% decrease. Two analysts lowered their price targets to $3.00, while two maintained their ratings with targets of $5.00 and $4.00. ThredUp has shown strong revenue growth and net margin but lags in ROE and ROA. Its debt-to-equity ratio is below industry norms.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 5:01 pm

VSTS

Analysts have provided mixed ratings for Vestis (NYSE:VSTS) over the past three months, with a recent shift towards a more bullish stance. The average 12-month price target for VSTS is now $21.00, up from $20.00, with a high estimate of $24.00 and a low of $20.00. The company operates in uniform rentals and workplace supplies in the US and Canada, showing strong profitability with a net margin of 22.4% and an ROE of 17.9%, but faces challenges with a high debt-to-equity ratio of 1.92.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 5:01 pm

MHK

Mohawk Industries (NYSE:MHK) received mixed analyst ratings with 2 bullish, 1 indifferent, and 1 somewhat bearish stance. The average 12-month price target is $102.5, down from $105.00. Analysts from Goldman Sachs, Barclays, Truist Securities, and Wells Fargo have updated their ratings and price targets. Mohawk faces revenue challenges with a -5.19% decline, a net margin of -27.49%, and an ROE of -9.83%. The company's market cap and debt management are strong, with a debt-to-equity ratio of 0.42.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 5:01 pm